Treatment of Human Thyroid Carcinoma Cells with the G47delta Oncolytic Herpes Simplex Virus |
Wang, Jia-Ni
(Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University)
Xu, Li-Hua (Department of Oncology and Hematology, The First Affiliated Hospital of Guangzhou Medical University) Zeng, Wei-Gen (Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University) Hu, Pan (Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University) Rabkin, Samuel D. (Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School) Liu, Ren-Rin (Breast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University) |
1 | Are C, Shaha AR (2006). Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol, 13, 453-64. DOI |
2 | Campadelli-Fiume G, De Giovanni C, Gatta V, et al (2011). Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol, 21, 213-26. DOI |
3 | Goldstein DJ, Weller SK (1988). Factor (s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology, 166, 41-51. DOI |
4 | Huang YY, Yu Z, Lin SF, et al (2007). Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab, 92, 1965-70. DOI |
5 | Lai ML, Faa G, Serra S, et al (2005). Rhabdoid tumor of the thyroid gland: a variant of anaplastic carcinoma. Arch Pathol Lab Med, 129, 55-7. |
6 | Li J, Zeng W, Huang Y, et al (2012). Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther, 19, 707-14. DOI |
7 | Lin SF, Gao SP, Price DL, et al (2008). Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res, 14, 1519-28. DOI |
8 | Martuza RL, Malick A, Markert JM, et al (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252, 854-6. DOI |
9 | Mohr I, Sternberg D, Ward S, et al (2001). A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol, 75, 5189-96. DOI |
10 | Pacini F, Castagna MG, Cipri C, et al (2010). Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol), 22, 475-85. DOI |
11 | Reinblatt M, Pin RH, Fong Y (2007). Herpes viral oncolysis: a novel cancer therapy. J Am Coll Surg, 205, S69-75. |
12 | Russell SJ, Peng KW, Bell JC (2012). Oncolytic virotherapy. Nat Biotechnol, 30, 658-70. DOI ScienceOn |
13 | Sherman SI, Wirth LJ, Droz JP, et al (2008). Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med, 359, 31-42. DOI |
14 | Sipos JA, Mazzaferri EL (2010). Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol), 22, 395-404. DOI |
15 | Varghese S, Rabkin SD (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther, 9, 967-78. DOI |
16 | Smallridge RC, Ain KB, Asa SL, et al (2012). American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid, 22, 1104-39. DOI |
17 | Todo T, Martuza RL, Rabkin SD, et al (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA, 98, 6396-401. DOI |
18 | Vanderpump MP (2011). The epidemiology of thyroid disease. Br Med Bull, 99, 39-51. DOI |
19 | Wang J, Hu P, Zeng M, et al (2011a). Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol, 40, 757-63. |
20 | Wang JN, Hu P, Zeng MS, et al (2011b). Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer, 30, 831-41. DOI |
21 | Yu Z, Eisenberg DP, Singh B, et al (2004). Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer, 112, 525-32. DOI |
22 | Zaman M, Fatima N, Sajjad Z, et al (2012). Threshold primary tumour sizes for nodal and distant metastases in papillary and follicular thyroid cancers. Asian Pac J Cancer Prev, 13, 2473-6. DOI |
23 | Zeng W, Hu P, Wu J, et al (2013a). The oncolytic herpes simplex virus vector G47 effectively targets breast cancer stem cells. Oncol Rep, 29, 1108-14. |
24 | Zeng WG, Li JJ, Hu P, et al (2013b). An oncolytic herpes simplex virus vector, G47Delta, synergizes with paclitaxel in the treatment of breast cancer. Oncol Rep, 29, 2355-61. |